The Medicines Company Acquires Targanta

The Medicines Company Acquires Targanta

News

WilmerHale client, The Medicines Company, announced yesterday that it had completed its acquisition of Targanta Therapeutics Corporation.

The Medicines Company completed the transaction through a cash tender offer followed by a short form merger. The Medicines Company paid Targanta stockholders $2.00 per share, net to the seller in cash, plus the contractual right to receive up to an additional $4.55 per share in contingent cash payments if specified regulatory and commercial milestones are achieved within agreed upon time periods.

With the consummation of the acquisition, Targanta has become a wholly owned subsidiary of The Medicines Company. Further details can be found by clicking here.

WilmerHale was legal advisor to The Medicines Company in this transaction, with a team including: partners David Redlick, Hal Leibowitz, Stuart Falber and Jeffrey Hermanson; counsels Marisa Murtagh and Jessica Lopez; and associates Dana Krueger and Erica Koenig.